메뉴 건너뛰기




Volumn 62, Issue 9, 2013, Pages 1511-1520

Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: A randomized phase II trial

Author keywords

5T4 tumor antigen; Biomarker; Cancer vaccine; Castration resistant prostate cancer; Docetaxel

Indexed keywords

BIOLOGICAL MARKER; DOCETAXEL; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MVA 5T4; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

EID: 84883462585     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1457-z     Document Type: Article
Times cited : (22)

References (35)
  • 1
  • 2
    • 0025974356 scopus 로고
    • Carcinoma of the prostate
    • 1985245 10.1056/NEJM199101243240406 1:STN:280:DyaK3M%2Foslyqsw%3D%3D
    • Gittes RF (1991) Carcinoma of the prostate. N Engl J Med 324(4):236-245
    • (1991) N Engl J Med , vol.324 , Issue.4 , pp. 236-245
    • Gittes, R.F.1
  • 4
    • 0027203411 scopus 로고
    • Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
    • 7687666 1:STN:280:DyaK3szivFGjsA%3D%3D
    • Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11(8):1566-1572
    • (1993) J Clin Oncol , vol.11 , Issue.8 , pp. 1566-1572
    • Scher, H.I.1    Kelly, W.K.2
  • 5
    • 0029084601 scopus 로고
    • The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer
    • 8620419 10.1002/1097-0142(19951015)76:8<1428: AID-CNCR2820760820>3. 0.CO;2-T 1:STN:280:DyaK283itlWqtQ%3D%3D
    • Small EJ, Srinivas S (1995) The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76(8):1428-1434
    • (1995) Cancer , vol.76 , Issue.8 , pp. 1428-1434
    • Small, E.J.1    Srinivas, S.2
  • 6
    • 0031001274 scopus 로고    scopus 로고
    • Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade
    • 9112515 10.1016/S0022-5347(01)64846-8 1:CAS:528:DyaK2sXmtVGjtrg%3D
    • Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR, Patterson AL, Klein E, Wajsman Z, Furr B, Chen Y, Kolvenbag GJ (1997) Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 157(5):1731-1735
    • (1997) J Urol , vol.157 , Issue.5 , pp. 1731-1735
    • Schellhammer, P.F.1    Venner, P.2    Haas, G.P.3    Small, E.J.4    Nieh, P.T.5    Seabaugh, D.R.6    Patterson, A.L.7    Klein, E.8    Wajsman, Z.9    Furr, B.10    Chen, Y.11    Kolvenbag, G.J.12
  • 7
    • 0029808474 scopus 로고    scopus 로고
    • Clinical trials in relapsed prostate cancer: Defining the target
    • 8931606 10.1093/jnci/88.22.1623 1:CAS:528:DyaK2sXjs1egug%3D%3D
    • Scher HI, Mazumdar M, Kelly WK (1996) Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst 88(22):1623-1634
    • (1996) J Natl Cancer Inst , vol.88 , Issue.22 , pp. 1623-1634
    • Scher, H.I.1    Mazumdar, M.2    Kelly, W.K.3
  • 8
    • 0031017228 scopus 로고    scopus 로고
    • Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
    • 8996165 1:CAS:528:DyaK2sXnsV2ltg%3D%3D
    • Small EJ, Vogelzang NJ (1997) Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 15(1):382-388
    • (1997) J Clin Oncol , vol.15 , Issue.1 , pp. 382-388
    • Small, E.J.1    Vogelzang, N.J.2
  • 9
    • 11144229621 scopus 로고    scopus 로고
    • Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer
    • 15623588 10.1158/1078-0432.CCR-04-1402 1:CAS:528:DC%2BD2cXhtFGjsrrE
    • Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R (2004) Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 10(24):8147-8151
    • (2004) Clin Cancer Res , vol.10 , Issue.24 , pp. 8147-8151
    • Dagher, R.1    Li, N.2    Abraham, S.3    Rahman, A.4    Sridhara, R.5    Pazdur, R.6
  • 13
    • 0025109257 scopus 로고
    • Immunohistological distribution of 5T4 antigen in normal and malignant tissues
    • 2404511 10.1038/bjc.1990.20 1:STN:280:DyaK3c7it1GrtQ%3D%3D
    • Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL (1990) Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 61:89-95
    • (1990) Br J Cancer , vol.61 , pp. 89-95
    • Southall, P.J.1    Boxer, G.M.2    Bagshawe, K.D.3    Hole, N.4    Bromley, M.5    Stern, P.L.6
  • 14
    • 0028324131 scopus 로고
    • Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma
    • 8180020 10.1038/bjc.1994.173 1:STN:280:DyaK2c3jsFCntg%3D%3D
    • Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, Stern PL (1994) Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 69:899-902
    • (1994) Br J Cancer , vol.69 , pp. 899-902
    • Starzynska, T.1    Marsh, P.J.2    Schofield, P.F.3    Roberts, S.A.4    Myers, K.A.5    Stern, P.L.6
  • 16
    • 48549088424 scopus 로고    scopus 로고
    • Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax): A phase 2 trial
    • 18528296 10.1097/CJI.0b013e31817deafd 1:CAS:528:DC%2BD1cXnslKjt74%3D
    • Amato RJ, Drury N, Naylor S, Jac J, Saxena S, Cao A, Hernandez-McClain J, Harrop R (2008) Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 31:577-585
    • (2008) J Immunother , vol.31 , pp. 577-585
    • Amato, R.J.1    Drury, N.2    Naylor, S.3    Jac, J.4    Saxena, S.5    Cao, A.6    Hernandez-Mcclain, J.7    Harrop, R.8
  • 17
    • 33745223435 scopus 로고    scopus 로고
    • Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial
    • 16740766 10.1158/1078-0432.CCR-05-2732 1:CAS:528:DC%2BD28XltFyis7c%3D
    • Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, Myers KA, Drury N, Kingsman SM, Hawkins RE, Carroll MW (2006) Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 12:3416-3424
    • (2006) Clin Cancer Res , vol.12 , pp. 3416-3424
    • Harrop, R.1    Connolly, N.2    Redchenko, I.3    Valle, J.4    Saunders, M.5    Ryan, M.G.6    Myers, K.A.7    Drury, N.8    Kingsman, S.M.9    Hawkins, R.E.10    Carroll, M.W.11
  • 18
  • 19
    • 42649138944 scopus 로고    scopus 로고
    • Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses
    • 18060404 10.1007/s00262-007-0428-7 1:CAS:528:DC%2BD1cXltFeqtLg%3D
    • Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Griffiths R, Steven N, Hawkins RE (2008) Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 57:977-986
    • (2008) Cancer Immunol Immunother , vol.57 , pp. 977-986
    • Harrop, R.1    Drury, N.2    Shingler, W.3    Chikoti, P.4    Redchenko, I.5    Carroll, M.W.6    Kingsman, S.M.7    Naylor, S.8    Griffiths, R.9    Steven, N.10    Hawkins, R.E.11
  • 21
    • 58149354757 scopus 로고    scopus 로고
    • Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: A phase II trial
    • 19010868 10.1158/1078-0432.CCR-08-0668 1:CAS:528:DC%2BD1cXhtlylur3M
    • Amato RJ, Shingler W, Naylor S, Jac J, Willis J, Saxena S, Hernandez-McClain J, Harrop R (2008) Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. Clin Cancer Res 14:7504-7510
    • (2008) Clin Cancer Res , vol.14 , pp. 7504-7510
    • Amato, R.J.1    Shingler, W.2    Naylor, S.3    Jac, J.4    Willis, J.5    Saxena, S.6    Hernandez-Mcclain, J.7    Harrop, R.8
  • 22
    • 68449100522 scopus 로고    scopus 로고
    • Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): A phase 2 trial
    • 19561532 10.1097/CJI.0b013e3181ace876 1:CAS:528:DC%2BD1MXovFSis7w%3D
    • Amato RJ, Shingler W, Goonewardena M, de Belin J, Naylor S, Jac J, Willis J, Saxena S, Hernandez-McClain J, Harrop R (2009) Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother 32:765-772
    • (2009) J Immunother , vol.32 , pp. 765-772
    • Amato, R.J.1    Shingler, W.2    Goonewardena, M.3    De Belin, J.4    Naylor, S.5    Jac, J.6    Willis, J.7    Saxena, S.8    Hernandez-Mcclain, J.9    Harrop, R.10
  • 23
    • 67449085969 scopus 로고    scopus 로고
    • Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha
    • 19342962 10.1097/CJI.0b013e31819d297e 1:CAS:528:DC%2BD1MXkvVGmtr4%3D
    • Hawkins RE, Macdermott C, Shablak A, Hamer C, Thistlethwaite F, Drury NL, Chikoti P, Shingler W, Naylor S, Harrop R (2009) Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother 32:424-429
    • (2009) J Immunother , vol.32 , pp. 424-429
    • Hawkins, R.E.1    Macdermott, C.2    Shablak, A.3    Hamer, C.4    Thistlethwaite, F.5    Drury, N.L.6    Chikoti, P.7    Shingler, W.8    Naylor, S.9    Harrop, R.10
  • 27
    • 84871004671 scopus 로고    scopus 로고
    • Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax)
    • 22692758 10.1007/s00262-012-1302-9 1:CAS:528:DC%2BC38XhslKhsbbJ
    • Harrop R, Treasure P, de Belin J, Kelleher M, Bolton G, Naylor S, Shingler WH (2012) Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax). Cancer Immunol Immunother 61(12):2283-2294
    • (2012) Cancer Immunol Immunother , vol.61 , Issue.12 , pp. 2283-2294
    • Harrop, R.1    Treasure, P.2    De Belin, J.3    Kelleher, M.4    Bolton, G.5    Naylor, S.6    Shingler, W.H.7
  • 28
    • 84865553173 scopus 로고    scopus 로고
    • Combination immunotherapy approaches
    • doi: 10.1093/annonc/mds262
    • Drake CG (2012) Combination immunotherapy approaches. Ann Oncol (Suppl 8):viii41-viii46. doi: 10.1093/annonc/mds262
    • (2012) Ann Oncol , Issue.SUPPL. 8
    • Drake, C.G.1
  • 29
    • 0033942857 scopus 로고    scopus 로고
    • The immunological effects of taxanes
    • 10941900 10.1007/s002620000122 1:CAS:528:DC%2BD3cXlvFymsb8%3D
    • Chan OT, Yang LX (2000) The immunological effects of taxanes. Cancer Immunol Immunother 49(4-5):181-185
    • (2000) Cancer Immunol Immunother , vol.49 , Issue.4-5 , pp. 181-185
    • Chan, O.T.1    Yang, L.X.2
  • 30
    • 0035286721 scopus 로고    scopus 로고
    • Enhancement of tumor radioresponse by docetaxel: Involvement of immune system
    • 11179493 1:CAS:528:DC%2BD3MXhsFGlt7Y%3D
    • Mason K, Staab A, Hunter N, McBride W, Petersen S, Terry N, Milas L (2001) Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 18(3):599-606
    • (2001) Int J Oncol , vol.18 , Issue.3 , pp. 599-606
    • Mason, K.1    Staab, A.2    Hunter, N.3    McBride, W.4    Petersen, S.5    Terry, N.6    Milas, L.7
  • 32
    • 50349091770 scopus 로고    scopus 로고
    • Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumour activity: Effects of docetaxel on immune enhancement
    • 10.1158/1078-0432.CCR-07-4025 1:CAS:528:DC%2BD1cXmslygtrc%3D
    • Garnett CT, Schlom J, Hodge JW (2008) Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumour activity: effects of docetaxel on immune enhancement. Clin Can Res 14(11):3536-3544
    • (2008) Clin Can Res , vol.14 , Issue.11 , pp. 3536-3544
    • Garnett, C.T.1    Schlom, J.2    Hodge, J.W.3
  • 34
    • 77957787538 scopus 로고    scopus 로고
    • Therapeutic cancer vaccines in prostate cancer: The paradox of improved survival without changes in time to progression
    • 20798195 10.1634/theoncologist.2010-0129
    • Madan RA, Gulley JL, Fojo T, Dahut WL (2010) Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 15(9):969-975
    • (2010) Oncologist , vol.15 , Issue.9 , pp. 969-975
    • Madan, R.A.1    Gulley, J.L.2    Fojo, T.3    Dahut, W.L.4
  • 35
    • 84877102343 scopus 로고    scopus 로고
    • Cancer vaccines: Identification of biomarkers predictive of clinical efficacy
    • 10.4161/hv.23032
    • Harrop R (2013) Cancer vaccines: identification of biomarkers predictive of clinical efficacy. Hum Vaccin Immunother 9(4):1-5
    • (2013) Hum Vaccin Immunother , vol.9 , Issue.4 , pp. 1-5
    • Harrop, R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.